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Abstract
Objective The aim of this study was to investigate
patients’ inhaler competence and satisfaction with the
Easyhaler dry powder inhaler.
Design Two open, uncontrolled, non-randomised studies.
Setting Real life based on patients attending 56 respira-
tory clinics in Hungary.
Participants Patients with asthma or chronic obstructive
pulmonary disease (COPD) (n = 1016).
Intervention In a 3-month study, adult patients (age range
18–88 years; n = 797) received twice-daily inhalations of
formoterol via Easyhaler, and in a consequential study
(from one visit to another, with 3–12 months in-between)
children and adolescents (age range 4–17 years; n = 219)
received salbutamol via Easyhaler as needed.
Main Outcome Measures Control of six Easyhaler
handling steps and patients’ satisfaction with Easyhaler
based on questionnaires.
Results Correct performances (minimum and maximum
of the six steps) were noticed after one demonstration in
92–98 % of the adults, 87–99 % of the elderly, 81–96 % of
the children and 83–99 % of the adolescents. These figures
had markedly increased at the last visit. Repeat instructions
were necessary in 26 % of the cases. Investigators found
Easyhaler easy to teach in 87 % of the patients and dif-
ficult in only 0.5 %. Patients found Easyhaler easy to
learn and use, and the patients’ (and parents’) satisfaction
with the inhaler was very high. Lung function values
[forced expiratory volume in 1 s (FEV1), forced vital
capacity (FVC), peak expiratory flow (PEF)] improved
statistically significantly during the studies, indicating good
inhaler competence and treatment adherence.
Conclusion Investigators found Easyhaler easy to teach
and patients found it easy to use, and their satisfaction with
the device was high.
1 Introduction
Inhalation is the preferred route of drug administration for
patients with airway diseases such as asthma and chronic
obstructive pulmonary disease (COPD) [1, 2]. Inhalation
delivers drugs directly to the airways and thereby the dose
can be small compared with oral therapy, and the risk of
systemic side effects is reduced. With b2-receptor agonists
and anticholinergics, direct delivery to the airways also
results in more rapid bronchodilation than oral treatment.
Furthermore, with the rapid and long-acting b2-agonist
(LABA) formoterol the duration of the bronchodilation is
enhanced compared with oral treatment [3]. Several types
of devices for delivery of inhaled drugs are available [4].
The effectiveness of inhaled drugs can be influenced by
factors such as age, gender, education, duration and
severity of disease, type of inhaler used, inhalation tech-
nique and many others [5, 6]. It has been shown that
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differences in effectiveness of inhalers have clinical
implications [7]. Meta-analyses, however, indicate that
when patients can apply the correct inhalation technique,
all inhalers can achieve the same therapeutic effects,
although different metered or delivered doses are required
[8, 9]. However, despite treatment guidelines [1, 2], control
of airway diseases in real life is rather poor [10, 11], inhaler
mishandling common, and often associated with reduced
disease control [12–14].
Easy and reliable inhalation may improve inhaler com-
petence and adherence to prescribed medications [15, 16].
Although it is apparent that no single inhaler can be ideal
for all patients, clinical evaluations have indicated, and
experts have expressed the opinion, that the dry powder
inhaler Easyhaler (Orion Corporation, Espoo, Finland)
comes very close to an ‘ideal inhaler’ [17]. This includes a
consistent fine particle dose across a wide range of inspi-
ratory flow rates [18], high lung deposition [19, 20] and
patient preferences [21, 22].
Patient preferences also play an important role when
prescribing an inhaler [23]. Several controlled clinical
studies have suggested that patient preferences and inhaler
competence are good when drugs have been administered
via Easyhaler and that the device is easy to teach, learn
and use [22, 24–27]. However, inhaler competence and
patient satisfaction with Easyhaler have not been tested in
real-life situations. This information is clearly warranted
[16]. In this study we therefore report the results of two
real-life studies where Easyhaler has been used for the
delivery of formoterol or salbutamol.
2 Aim of the Studies
The primary aims of the studies were to evaluate the
patients’ inhaler competence and their satisfaction with
Easyhaler in real-life settings.
3 Material and Methods
3.1 Study A
This was an open, uncontrolled, non-randomized, 3-month,
multicentre study in 46 study centres evaluating the effi-
cacy, safety and patient satisfaction of formoterol Easy-
haler in patients with asthma or COPD requiring
treatment with an inhaled long-acting bronchodilator
(LABA) according to treatment guidelines. Ethics com-
mittee approval was obtained via the Central National
Procedure. The study protocol was approved under the
code 22606-0/2010-1018EKU (886/PI/10).
3.1.1 Patients
Study subjects were selected from the patient population
routinely attending the clinics. Patients aged from 18 years
(no upper age limit) could be included. The asthma patients
should not have been earlier treated with a LABA, or they
should be patients not well controlled on actual therapy
without a LABA, or patients who, based on the manufac-
turer’s instructions, were unable to use their current
inhaler(s) in a correct way.
Eligible patients were those requiring add-on treatment
with LABA, according to therapeutic guidelines [1]. These
included asthmatic patients suffering from persistent,
moderate asthma (FEV1 60–80 % of predicted normal
values and/or an FEV1 or PEF variability [30 %), severe
asthmatic patients (FEV1 corresponding to \60 % of pre-
dicted values or PEF variability [30 %), patients with
moderate COPD (post-bronchodilator FEV1 ranging from
C50 to\80 % of predicted normal values) or more severe
COPD patients (post-bronchodilator FEV1 \50 %).
Patients with known hypersensitivity to formoterol or lac-
tose were excluded.
3.1.2 Medication
The patients—asthma patients as well as patients with
COPD—were treated with formoterol Easyhaler 12 lg
twice daily. The asthma patients also used an inhaled
corticosteroid as controller therapy according to the Global
Initiative for Asthma (GINA) guidelines [1]. Patients with
COPD always received formoterol Easyhaler 12 lg twice
daily.
3.1.3 Methods
There were three clinic visits in the study. First, a screening
visit (visit 1) when demographic data were recorded,
including smoking history and type of inhaler device used.
At all three visits, pulmonary function testing (FEV1, FVC
and PEF) was performed. The lung function measurements
were not standardized, neither in terms of use of inhaled
b2-agonists before the tests nor in terms of time of the day.
Patients were instructed in the use of Easyhaler and they
received a questionnaire to be filled in during the study.
The instruction of Easyhaler contained six handling steps:
1. Take off the blue cap
2. Shake the device in an upright position
3. Push the top of the device until you here a click
4. Exhale, put the mouthpiece into your mouth and inhale
deeply
5. Repeat steps 2–4 if more than one dose is prescribed
6. Put the blue cap back on.
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The investigator recorded how many times it was nec-
essary to repeat the instructions until the patient could
demonstrate the correct use of the device. The investigator
also answered the question of how easy it was to teach the
patient in the correct use of Easyhaler.
Visit 2 took place 1 week later (or within 30 days from
visit 1), when handling of Easyhaler was checked and lung
function tests were performed. Lung function tests were
performed with standard equipment available at the clinics.
Visit 3 took place after 3 months, when handling of
Easyhaler was checked again, lung function tests were
performed and the filled-in questionnaire was given back to
the investigator.
At all three visits, measurements of heart rate and blood
pressure were performed as part of an overall safety
evaluation.
3.2 Study B
This was an open, uncontrolled, non-randomized, multi-
centre study at ten centres evaluating the efficacy, safety
and patient satisfaction of salbutamol Easyhaler used as
needed in children and adolescents with any stage of
asthma. Results were obtained at the next clinical visit,
which usually took place after 3–4 months but always
within 1 year from the first visit. Ethics committee
approval was obtained via the Central National Procedure.
The study protocol was approved under the code 10732-1/
2011-EKU (645/PI/11).
3.2.1 Patients
Patients should have been 4–17 years of age and using
salbutamol pressurized metered dose inhaler (pMDI) with a
spacer for temporary relief of symptoms or prophylacti-
cally to avoid exercise- or allergen-induced bronchocon-
striction. Children currently using a b2-agonist pMDI
attached to a spacer and who may prefer to use a smaller
device could also be included. Patients with known
hypersensitivity to salbutamol or lactose were excluded.
3.2.2 Medication
Patients were asked to inhale one 200 lg dose of salbuta-
mol as needed depending on symptoms but not more than
four doses per day. Regular maintenance treatment with
salbutamol should be avoided.
3.2.3 Methods
There were two clinic visits in the study. First, a screening
visit (visit 1) when demographic data and type of inhaler
device and spacer used were recorded. Patients were
instructed in the use of Easyhaler (as for Study A). Visit 2
took place within 1 year from visit 1 depending on the
asthma stage (intervals 1, 3, 6 or 12 months), when parents
and children filled in a questionnaire. At visits 1 and 2, lung
function tests were performed (FEV1, FVC and PEF) with
standard equipment available at the clinics.
At visit 1, the investigators filled in a questionnaire
about teaching of Easyhaler and how easy it was for
patients to learn the correct use.
4 Statistical Analyses
Changes in lung function variables were analysed using a
mixed model for repeated measures (MMRM) and SAS
software (SAS Institute Inc., Cary, NC, USA) [28]. Each lung
function variable (FEV1, FVC and PEF) was modelled sep-
arately using MMRM, including age group, visit and age
group by visit interaction, as independent variables. Repeated
statement was used to specify the repeated measures factor
(visit) and the subject variable (subject) identifying obser-
vations that are correlated. Differences between visits in lung
functions were obtained using the estimate statement in SAS
Proc Mixed. Estimates of means of each lung function are
least square means from the statistical models.
5 Results
There was a total of 797 patients included in study A and
219 in study B. Demographic data of the study patients is
shown in Table 1 divided by age (children, adolescents,
adults, elderly) and diagnosis (asthma, COPD). Gender,
age, lung function values as predicted normal values and
smoking habits are also reported.
The patients’ previous inhaler use is presented in
Table 2.
5.1 Investigators’ Evaluation of Teaching Patients
the Use of Easyhaler
In 92 % of the patients with asthma and 83 % of the
patients with COPD the investigators reported that it was
easy to teach the correct use of Easyhaler. Correct use of
Easyhaler was achieved with just one demonstration in
77 % of the asthma patients and 72 % of the patients with
COPD. In relation to age, the correct use of Easyhaler
was achieved with one demonstration in 64 % of the
children, 76 % of the adolescents, 78 % of the adults and
70 % of the elderly. Teaching was reported to be hard in
one child, one adult and three elderly patients. In 13 % of
the patients, teaching was considered not easy but not hard,
i.e. something in-between.
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The development of the correct manoeuvres over time is
shown in Table 3 for adults and the elderly (study A) and
in Table 4 for children and adolescents (study B). A
gradual improvement in the use of Easyhaler was noted,
particularly in children and adolescents whose correct use
was not so good at the first training compared with the
adults and elderly patients.
5.2 Patients’ Opinion About How Easy it was to Learn
the Correct Use of Easyhaler
Patients’ opinion about how easy it was to learn the correct
use of Easyhaler is shown in Table 5. The vast majority
of patients found the use of Easyhaler very easy or easy to
learn. There were no major differences between the age
groups, with the exception that fewer elderly patients
reported the use of Easyhaler to be very easy. Compared
with their earlier inhalation devices, 88 % of the children,
86 % of the adolescents, 60 % of the adults and 69 % of
the elderly found Easyhaler easier to learn. Only eight
patients found Easyhaler more difficult to learn compared
with their previous device. The rest of the patients did not
see any difference in the learning procedure.
Of the patients with asthma, 76 % found Easyhaler
easier to use compared with their previous device and 23 %
found no difference. Among patients with COPD, the
corresponding figures were 62 and 37 %.
5.3 Patients’ Satisfaction with the Use of Easyhaler
Patients’ satisfaction with the use of Easyhaler is shown
in Table 6. A total of 95 % of the patients were very sat-
isfied (42.7 %) or satisfied (52.7 %) with their use of
Easyhaler. No major differences were seen between the
four age groups, although children (and their parents) and
adolescents were more often very satisfied compared with
the adults and elderly patients.
Patients with asthma were more often very satisfied with
Easyhaler (52.6 %) compared with patients with COPD
(33.4 %). The percentages of patients reporting that they
were satisfied were 44.4 and 61.1 %, respectively.
Table 1 Demographic data of
the patients
COPD chronic obstructive
pulmonary disease, FEV1 forced
expiratory volume in 1 s, FVC
forced vital capacity, NC not
calculated, NR not registered,
PEF peak expiratory flow, pred
predicted
Children Adolescents Adults Elderly Total
No. of pts 139 80 582 215 1016
Gender
Male, n (%) 80 (58) 55 (69) 240 (42) 102 (47) 478 (47)
Female, n (%) 59 (42) 25 (31) 338 (58) 111 (53) 532 (53)
Not reported 0 0 4 (0) 2 (0) 6 (0)
Mean age, years (SD) 7.6 (2.2) 14.5 (1.6) 51.2 (11.1) 72.9 (5.4) NC
Age range, years 3–11 12–17 18–65 66–88 3–88
Diagnosis
Asthma 139 80 200 51 470
COPD 0 0 344 153 497
Not recorded 0 0 38 11 49
Lung function (mean, SD)
FEV1, % pred 100.1 (18.9) 95.8 (14.2) 65.3 (12.3) 61.9 (12.9) NC
FVC, % pred 97.3 (19.1) 96.9 (16.0) 80.0 (15.2) 76.9 (17.5) NC
PEF, % pred 91.9 (19.7) 98.7 (20.0) 59.6 (17.7) 55.0 (16.3) NC
Smokers (%) NR NR NC
Never smoker 30.7 32.2
Ex-smoker 22.3 42.4
Smoker 47.0 25.4
Table 2 Inhaler device used by the patients before the study
Children Adolescents Adults Elderly Total
pMDI ± spacer 115 75 159 64 413
Diskus 0 1 22 13 36
Easyhaler 2 0 12 1 15
Handihaler 0 0 33 17 50
Turbuhaler 0 0 23 5 28
Other 0 0 52 13 65
Not reported 22 4 138 48 212
More than one
device
0 0 143 54 197
Total 139 80 582 215 1016
pMDI pressurized metered dose inhaler
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5.4 Lung Function with the Use of Easyhaler
Lung function values at visit 1 (before the use of Easy-
haler) and at the follow-up visits are shown in Fig. 1 for
adults and the elderly (study A), and in Fig. 2 for children
and adolescents (study B). Clear improvements in lung
function were noticed in all patient groups, indicating good
inhaler competence and adherence to treatment. The
increases in all four age groups and for all three lung
function variables (FEV1, FVC and PEF) were statistically
highly significant.
6 Discussion
Results of randomized controlled trials may not predict
effectiveness of inhaled drugs, and authors have expressed
concern about the external validity or generalizability of
trial results [29, 30]. Patients included in controlled trials
receive adequate inhaler training and have to demonstrate
and maintain proper inhaler competence. Moreover, most
randomized controlled trials are short-term trials and there
is some evidence that, in the real world, inhaler technique
deteriorates over time [31] and that may affect clinical
outcomes [32, 33]. Thus, results of real-world studies are
warranted [16].
In this study we report the results of two multicentre,
real-life studies with the use of the dry powder inhaler,
Easyhaler: one with twice-daily inhalations of formoterol
in patients with asthma or COPD, and one with as-needed
inhalations of salbutamol in children and adolescents with
asthma. All together, more than 1000 patients were inclu-
ded and they represent a wide age range, from 3 to 88 years
of age. The studies were also of a sufficiently long dura-
tion—3 months and up to 1 year, respectively—in order to
make reliable user evaluations possible.
In the vast majority of the cases the investigators
found Easyhaler easy to teach, and second or third
instructions were necessary in only 26 % of the patients.
The instruction to shake the inhaler appeared, for the
patients, to be the most difficult manoeuvre to remember.
After one instruction a total of 81 % of the children,
83 % of the adolescents, 87 % of the elderly and 92 %
of the adults performed all manoeuvres correctly. At the
last study visit these figures had increased to a minimum
Table 3 The correct performance of Easyhaler administration steps
in the percentage of adults and elderly patients with asthma or COPD
(study A)
Adults (n = 574) Elderly (n = 214)
Visit 1 Visit 2 Visit 3 Visit 1 Visit 2 Visit 3
Manoeuvres
Take off the cap
No 1.6 1.2 1.1 1.4 1.4 1.4
Yes 98.4 98.8 98.9 98.6 98.6 98.6
Shake the inhaler
No 8.3 2.3 1.2 11.5 3.3 1.9
Yes 91.7 97.7 98.8 88.5 96.7 98.1
Click
No 3.2 1.9 1.4 4.3 1.4 2.4
Yes 96.8 98.1 98.6 95.7 98.6 97.6
Inhale
No 7.3 1.9 0.9 12.7 4.7 4.3
Yes 92.7 98.1 99.1 87.3 95.3 95.7
Repeat if needed
No 6.0 4.8 4.6 8.2 4.3 5.8
Yes 94.0 95.2 95.4 91.8 95.7 94.2
Put on the cap
No 3.4 2.8 2.3 5.7 1.9 2.9
Yes 96.6 97.2 97.7 94.3 98.1 97.1
All steps correct
No 22.5 10.8 9.8 29.8 11.2 11.6
Yes 77.5 89.2 90.2 70.2 88.8 88.4
COPD chronic obstructive pulmonary disease
Table 4 The correct performance of Easyhaler administration steps
in the percentage of children and adolescents with asthma (study B)
Children (n = 139) Adolescents (n = 80)
Visit 1 Visit 2 Visit 1 Visit 2
Manoeuvres
Take off the cap
No 4.3 2.9 3.8 0
Yes 95.7 97.1 96.3 100
Shake the inhaler
No 19.4 5.8 17.5 1.3
Yes 80.6 94.2 82.5 98.8
Click
No 6.5 2.2 1.3 0
Yes 93.5 97.8 98.8 100
Inhale
No 14.6 7.2 17.5 1.3
Yes 85.4 92.8 82.5 98.8
Repeat if needed
No 8.6 7.2 6.3 5.0
Yes 91.4 92.8 93.8 95.0
Put on the cap
No 4.3 5.0 1.3 6.3
Yes 95.7 95.0 98.8 93.8
All steps correct
No 38.1 16.5 35.0 11.3
Yes 61.9 83.5 65.0 88.8
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of 93 %. The improved lung function values in all age
groups, and both in asthma and COPD patients, also
indicate that the inhaler competence remained good, as
well as treatment adherence. It has been suggested that
the ease of use of an inhaler device may correlate with
inhaler competence and thereby with adherence to
treatment [14, 15].
The patients reported that it was easy to learn how to use
Easyhaler and they were satisfied or very satisfied with
the use of the inhaler.
The high figures for patient satisfaction and patients’
reports on how easy it was to learn the correct use of
Easyhaler may suggest that this device is the most easy to
use. That conclusion cannot, however, be drawn as no real
comparison has been made.
Our study also has other limitations. Most patients with
airway diseases have used inhaler devices previously and
have a good idea about inhalation manoeuvres in general.
Therefore it would have been more reliable to expose
patients not previously using inhalers (or volunteers) to the
devices to be evaluated. The majority of patients whose
previous inhaler devices were recorded had used a pMDI,
which is the most difficult of all inhalers to use correctly
[34, 35]. Almost one-fifth of the patients had used multiple
devices. Therefore, it is not surprising that more than 50 %
of both the asthma and COPD patients found Easyhaler
easier to use than their previous device. For the same
Table 5 Patients’ opinion
about the ease of learning the
correct use of Easyhaler
[n (%)]
Ease of learning the correct use
of Easyhaler
Children
(n = 138)
Adolescent
(n = 80)
Adults
(n = 575)
Elderly
(n = 215)
All
(n = 1008)
Very easy 68 (49) 48 (60) 270 (47) 73 (34) 459 (46)
Easy 68 (49) 32 (40) 296 (51) 132 (61) 528 (52)
Difficult 1 (0.7) 0 9 (2) 10 (5) 20 (2)
Very difficult 1 (0.7) 0 0 0 1 (0)
Table 6 Patients’ satisfaction
with the use of Easyhaler
[n (%)]
Degree of
satisfaction
Children
(n = 136)
Adolescents
(n = 80)
Adults
(n = 571)
Elderly
(n = 214)
All
(n = 1001)
Very satisfied 76 (56) 47 (59) 224 (39) 80 (37) 427 (43)
Satisfied 57 (42) 31 (39) 322 (56) 118 (55) 528 (53)
Moderately
satisfied
3 (2) 2 (2) 23 (4) 14 (7) 42 (4)
Dissatisfied 0 0 2 (1) 2 (1) 4 (0)
Fig. 1 FEV1, FVC and PEF as percent predicted normal values in
adults and the elderly with asthma or COPD at the three clinic visits
in the study. COPD chronic obstructive pulmonary disease, FEV1
forced expiratory volume in 1 s, FVC forced vital capacity, PEF peak
expiratory flow
Fig. 2 FEV1, FVC and PEF as percent predicted normal values in
children and adolescents with asthma at the two clinic visits in the
study. FEV1 forced expiratory volume in 1 s, FVC forced vital
capacity, PEF peak expiratory flow
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reason, most patients reported that they were satisfied or
very satisfied with Easyhaler. For children left to use a
pMDI with a spacer (and maybe with a face mask) for
temporary relief of symptoms, a change to a less bulky but
effective device is also easy to appreciate. A further limi-
tation is that a crossover design was not used. It would have
been an advantage to also evaluate and record the
manoeuvres with the previous devices or with another dry
powder inhaler.
Problems encountered by patients not using inhaler
devices correctly have led to the concept of one universal
‘ideal’ inhaler [16, 17]. However, no inhaler is 100 %
ideal. The inhalers on the market are ‘Realhalers’, not
‘Idealhalers’ and physicians have to weigh up the pros and
cons for each device to make the most appropriate choice
[36]. An ‘ideal inhaler’ should be portable, easy to use,
‘nice looking’, inexpensive, loaded with multiple doses,
have a dose counter, and show dosing accuracy and con-
sistency over a wide range of inspiratory flows. To avoid
hand–mouth dyscoordination, the device should be actu-
ated and driven by the inspiratory flow. It should be suit-
able for use in both acute and chronic situations, i.e. have a
high versatility. Technically, inhalation through the ‘ideal
inhaler’ should result in a high lung deposition, thereby
reducing the nominal doses to be administered and the risk
of local side effects (inhaled corticosteroids) and systemic
effects. The variability in lung deposited doses should be
minimal. It is well known that pMDIs, compared with dry
powder inhalers, live up to only a few of these require-
ments [37–39]. There are also obvious differences between
dry powder inhalers, where the multidose, reservoir-type
dry powder inhalers appear to have a clear advantage [7,
37, 39]. Easyhaler, with its dose consistency over a wide
range of inspiratory flows, is an inhaler device that comes
very close to being an ‘Idealhaler’ [16, 17, 27].
Bearing in mind the inherent variability among patients,
it may be preferable that inhalers should be matched to the
patient [16]. The results of our two studies show that
Easyhaler can be matched to a large majority of patients
with airway diseases irrespective of age, and that they are
satisfied with its use. Easyhaler could therefore be one
component in the strategy by which asthma management
can be improved as requested by the Brussels Declaration
[40].
7 Conclusion
In patients with asthma or COPD and representing a wide
range of ages and disease severities, investigators found
Easyhaler easy to teach and that patients found it easy to
use and their satisfaction with the device was high. Lung
function improved markedly and significantly during the
studies, indicating persistent good inhaler competence and
treatment adherence. As a device, Easyhaler appears to
come close to an ‘ideal’ inhaler.
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